|
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
Universidade Santiago de Compostela (Group 1)
 |
Coordinator
We have 20-year experience in the development of polymer nanocarriers for the delivery of macromolecules across mucosal surfaces. Within the TRANS-INT project we plan to develop advanced core-shell nanocarriers specifically adapted for the encapsulation and controlled delivery of peptides.
[go to website]
|
Universidade Santiago de Compostela (Group 2)
 |
Prof. Diéguez activiy focuses on endocrine research in particular in obesity and intermediary metabolism. Prof. Diéguez's group will conduct a detalied phenotypic assessment and glucose homeostasis tests in different models of diabetes/obesity for the selected drug candidates.
[go to website]
|
University College Dublin
 |
Our group will formulate hyaluronic acid/protamine nanoparticulates as peptide carriers. We will also evaluate their in vivo interaction with epithelial barriers and biodistribution in rats, and the preliminar immunological response in mice.
[go to website]
|
Université catholique de Louvain
 |
Prof. Preat's group will assess the transport of the nanoparticle prototypes using mono- or co-culture of Caco-2 cells. Prof. Preat's group will also contribute to peptide encapsulation.
[go to website]
|
| |
University College London
 |
Dr. Schatzlein's group will synthesise biocompatible amphiphilic polymers to create nano-sized micellar clusters that improve bioavailability of hydrophobic drugs and peptides across the gut.
[go to website]
|
| |
Veneto Nanotech
 |
 Dr. Federico Benetti
Veneto Nanotech will evaluate in vitro the transport of the nanocarriers through the intestinal mucosa, as well as their intestinal biodistribution and the immunological responses that are triggered locally.
[go to website]
|
| |
Sigmoid Pharma Limited
 |
Within the TRANS-INT project, Sigmoid aims to provide SmPill based formulations to ensure optimal targeted release of stable nanocarriers within the gastrointestinal tract. Sigmoid will ensure that the final formulation is manufactured under GMP conditions and is suitable for industrial/clinical applications.
[go to website]
|
| |
Université d’Angers
 |
Our group will design new lipid nanocapsules to improve the bioavailability of selected peptides after oral administration. The nanocapsules and their interaction with the intestinal fluids and the mucus will be characterised with a range of techniques available at our lab.
[go to website]
|
| |
Medizinische Hochschule Hannover
 |
MHH role would be to conduct explorative toxicology studies with the most promising nanocarriers to better understand possible safety concerns associated to them. MHH will also be in charge of GLP-toxicology studies of the peptide-loaded nanocarriers.
[go to website]
|
| |
Institut de Recerca Biomèdica
 |
IRB work will be focused on the use of cell-penetrating peptides and GIT-shuttles to decorate the nanocarriers in order to improve their transport across the intestinal mucosa.
[go to website]
|
| |
Uppsala Universitet
 |
UU will provide a model based on freshly isolated human intestine/colon for nanoparticle uptake studies and will also investigate the tissues transport capacity and response to the nanoparticles
[go to website]
|
| |
Istituto Oncologico Veneto I.R.C.C.S.
 |
IOV will determine the effects of nanocarriers on the activation or modulation of the immune system, both at the intestinal mucosa and the secondary lymphoid organs. The studies will be performed in vivo in mouse models as well as on in vitro derived myeloid cells.
[go to website]
|
| |
Seroscience Ltd.
 |
Using various in vitro and in vivo tests, SeroScience Ltd. will explore the risk of immune toxicity (immunogenicity, immune reactivity, allergenicity, immune suppression) of orally administered drug candidates selected by the TRANS-INT consortium.
[go to website]
|
| |
Sanofi-aventis recherche & développement (SARD)
 |
Sanofi will provide the peptides and will evaluate in-vivo several oral formulations containing these peptides. Efficacy will be assessed in the chronic constriction injury model compared to clinical reference drugs. Sanofi will also conduct pharmacokinetics studies and exploratory safety evaluation of the loaded nanocarriers.
[go to website]
|
University College Cork
 |
UCC will formulate and characterize peptide-entrapped cyclodextrin nanocarriers and will use the rat and pig animal models to assess lymphatic transport, bioavailability and pharmacokinetics of nanocarriers.
[go to website]
|
|
|
Prof. Caitriona O’Driscoll
